ClassID:

96991

C07K14/5759 - CPC Classification

Classification description:

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Products of obesity genes, e.g. leptin, obese (OB), tub, fat

Recent Application in this class:
#1
20250320301
2025-10-16

METHODS OF TREATMENT USING A LEPTIN RECEPTOR AGONIST ANTIBODY

#2
20250235508
2025-07-24

MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF

#3
20250041368
2025-02-06

Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling

#4
20250009824
2025-01-09

Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling

#5
20240271082
2024-08-15

GENETICALLY-MODIFIED SACCHAROMYCES YEAST STRAINS AS PREVENTATIVE AND THERAPEUTIC AGENTS

#6
20240207325
2024-06-27

Pancreatic Islets as Protein Factories

#7
20240141009
2024-05-02

PEPTIDE USED FOR IMMUNOTHERAPEUTICS

#8
20230365695
2023-11-16

COILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF

#9
20230331769
2023-10-19

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#10
20230256041
2023-08-17

Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling

#11
20230250132
2023-08-10

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#12
20230242577
2023-08-03

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#13
20230242576
2023-08-03

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#14
20230242575
2023-08-03

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#15
20230242574
2023-08-03

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#16
20230242573
2023-08-03

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#17
20230193226
2023-06-22

Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin

#18
20230183286
2023-06-15

NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA

#19
20230115655
2023-04-13

ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION

#20
20230100744
2023-03-30

METHODS FOR ENRICHING MARROW INFILTRATING LYMPHOCYTES ("MILS"), COMPOSITIONS CONTAINING ENRICHED MILS, AND METHODS OF USING ENRICHED MILS

#21
20230074446
2023-03-09

ADIPONECTIN PEPTIDOMIMETICS FOR TREATING OCULAR DISORDERS

#22
20230054612
2023-02-23

FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES

#23
20220331393
2022-10-20

ADIPONECTIN PEPTIDOMIMETICS FOR TREATING OCULAR DISORDERS

#24
20220280641
2022-09-08

METHODS OF TREATMENT USING A LEPTIN RECEPTOR AGONIST ANTIBODY

#25
20220162324
2022-05-26

CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF

#26
20220144912
2022-05-12

Leptin immunogens, hybridoma cells, monoclonal antibodies, polyclonal antibodies and use thereof

#27
20220072104
2022-03-10

MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF

#28
20210324031
2021-10-21

COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME

#29
20210162011
2021-06-03

Methods for Improving Leptin Sensitivity for the Treatment of Obesity and Diabetes

#30
20210128671
2021-05-06

Adiponectin peptidomimetics for treating ocular disorders

#31
20200362006
2020-11-19

Engineered polypeptides having enhanced duration of action

#32
20200330534
2020-10-22

Expression of metabolic modulators in tumor microenvironment to improve tumor therapy

#33
20200270353
2020-08-27

Coiled coil immunoglobulin fusion proteins and compositions thereof

#34
20200255492
2020-08-13

LEPTIN PEPTIDES AND THEIR USE FOR TREATING NEUROLOGICAL DISORDERS

#35
20200247864
2020-08-06

Combinatorial gene construct and non-viral delivery for anti-obesity

#36
20200223895
2020-07-16

Therapeutic targeting of SET1B/compass pathway for treating cancers

#37
20200190132
2020-06-18

3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA

#38
20200085907
2020-03-19

Adiponectin peptidomimetics for treating ocular disorders

#39
20200048323
2020-02-13

Peptide having anti-obesity and anti-diabetes efficacy and use thereof

#40
20190382439
2019-12-19

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#41
20190284540
2019-09-19

Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin

#42
20190203192
2019-07-04

KLK6-MEDIATED CNS-SPECIFIC ANTIBODY PRODRUG ACTIVATION

#43
20190085042
2019-03-21

FUSION POLYPEPTIDE COMPRISING THE EXTRACELLULAR BINDING DOMAIN OF GROWTH HORMONE RECEPTOR

#44
20190010199
2019-01-10

Fusokines involving cytokines with strongly reduced receptor binding affinities

#45
20190010192
2019-01-10

Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences

#46
20190000928
2019-01-03

MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF

#47
20180305430
2018-10-25

Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity

#48
20180298051
2018-10-18

Methods and compositions related to functional polypeptides embedded in heterologous protein scaffolds

#49
20180230189
2018-08-16

Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1

#50
20180161390
2018-06-14

Adiponectin peptidomimetics for treating ocular disorders

#51
20180155404
2018-06-07

Fusokines involving cytokines with strongly reduced receptor binding affinities

#52
20180088134
2018-03-29

Compilation of detection reagents, in-vitro method for detecting mutated leptin, and use of a detection reagent

#53
20180078616
2018-03-22

Adiponectin peptidomimetics for treating ocular disorders

#54
20180050094
2018-02-22

Leptin active peptide having cd loop and E helix region mutations, coding gene thereof, and application thereof

#55
20180050093
2018-02-22

Leptin active peptide having D helix region mutations, coding gene thereof, and application thereof

#56
20180009870
2018-01-11

Therapeutic targeting of SET1B/compass pathway for treating cancers

#57
20180009869
2018-01-11

Fusion Protein Comprising Leptin and Methods for Producing and Using the Same

#58
20180002368
2018-01-04

3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA

#59
20170335361
2017-11-23

Method of highly expressing target protein from plant using RbcS fusion protein and method of preparing composition for oral administration of medical protein using target protein expression plant body

#60
20170306030
2017-10-26

CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF

#61
20170037103
2017-02-09

Anti-obesity compounds derived from neuromedin U

#62
20160263235
2016-09-15

PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF

#63
20160222077
2016-08-04

Composition comprising peptide derived from adiponectin

#64
20160207974
2016-07-21

Engineered polypeptides having enhanced duration of action and reduced immunogenicity

#65
20160159920
2016-06-09

Coiled coil immunoglobulin fusion proteins and compositions thereof

#66
20160137709
2016-05-19

ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION

#67
20160083446
2016-03-24

Chimeric leptin polypeptide and method of using the same

#68
20150376264
2015-12-31

Bovine fusion antibodies

#69
20150366983
2015-12-24

Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide

#70
20150329619
2015-11-19

Albumin fusion proteins

#71
20150203568
2015-07-23

Albumin fusion proteins

#72
20140256621
2014-09-11

ENGINEERED POYPEPTIDES HAVING ENHANCED DURATION OF ACTION AND REDUCED IMMUNOGENICITY

#73
20140242111
2014-08-28

Engineered bacteria for oral delivery of glucoregulatory proteins

#74
20140227267
2014-08-14

Bovine fusion antibodies

#75
20140219983
2014-08-07

Suppression of prostate cancer using a targeted clostridial neurotoxin

#76
20140194343
2014-07-10

CTRP6 which can be used as therapeutic and prophylactic agent for autoimmune diseases

#77
20140086949
2014-03-27

Ghrelin mimetic polypeptide hapten immunoconjugates having improved solubility and immunogenicity and methods of use thereof

#78
20140057833
2014-02-27

Adiponectin receptor agonists and methods of use

#79
20140018290
2014-01-16

LEPTIN DERIVATIVES

#80
20130274182
2013-10-17

ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION

#81
20130133089
2013-05-23

High affinity leptins and leptin antagonists

#82
20120277158
2012-11-01

COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS

#83
20120149636
2012-06-14

Modified leptin polypeptides and their uses

#84
20120142585
2012-06-07

Leptin antagonist and methods of use

#85
20120115776
2012-05-10

Adiponectin-containing eating behavior control agent for oral administration

#86
20120108504
2012-05-03

Leptin agonist and methods of use

#87
20120046221
2012-02-23

Albumin fusion proteins

#88
20110288011
2011-11-24

PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF

#89
20110288009
2011-11-24

LEPTIN AND LEPTIN ANALOG CONJUGATES AND USES THEREOF

#90
20110274658
2011-11-10

Chimeric activators: quantitatively designed protein therapeutics and uses thereof

#91
20110256123
2011-10-20

Methods for decreasing leptin levels or activity for treating inflammation

#92
20110236929
2011-09-29

BL21 strain lacking a functional group II capsular gene cluster

#93
20110218332
2011-09-08

Nucleic acids encoding modulators of body weight

#94
20110190473
2011-08-04

Leptin peptide antagonists

#95
20110165137
2011-07-07

Polypeptides that bind to and inhibit secretion from growth hormone secreting cells

#96
20110092673
2011-04-21

Isolated antibodies against biologically active leptin-related peptides

#97
20110092417
2011-04-21

LEPTIN FUSION PROTEINS

#98
20110059855
2011-03-10

Use of adiponectin for the diagnosis and/or treatment of presbycusis

#99
20110015124
2011-01-20

Leptin agonist and methods of use

#100
20110009312
2011-01-13

Albumin fusion proteins

#101
20100331528
2010-12-30

Isolated antibodies against biologically active leptin-related peptides

#102
20100269180
2010-10-21

METHODS, COMPOSITIONS AND TRANSGENIC MODELS RELATED TO THE INTERACTION OF T-CADHERIN AND ADIPONECTIN

#103
20100222278
2010-09-02

USE OF LEPTIN FOR THE PREVENTION OF EXCESS BODY WEIGHT AND COMPOSITION CONTAINING LEPTIN

#104
20100099649
2010-04-22

Site-specific chemical modification of proteins at their N-termini, enabling the formation of homogeneous adducts

#105
20100016216
2010-01-21

Adiponectin and uses thereof

#106
20090318677
2009-12-24

Modulators of body weight, corresponding nucleic acids and proteins

#107
20090209460
2009-08-20

COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED METABOLIC DISORDERS

#108
20090181885
2009-07-16

Compounds and their effects on feeding behaviour

#109
20090142804
2009-06-04

Process For Preparing Serine-Rich Protein Employing Cysteine Synthase (CYSK) Gene

#110
20090142351
2009-06-04

Human and rat PGC-3, PPAR-gamma coactivations and splice variants thereof

#111
20090118178
2009-05-07

Y4 selective receptor agonists for therapeutic interventions

#112
20090099085
2009-04-16

Amylin derivatives

#113
20090099076
2009-04-16

OBG3 globular head and uses thereof

#114
20090099073
2009-04-16

Albumin Fusion Proteins

#115
20090093402
2009-04-09

Albumin Fusion Proteins

#116
20090029919
2009-01-29

Method of reducing or inhibiting ObR signaling using a leptin antagonist consisting of SEQ id No: 2

#117
20080312154
2008-12-18

ADMINISTRATION OF ADIPOCYTOKINE AND ADIPONECTIN FOR TREATING HEADACHE AND METHODS OF DIAGNOSING HEADACHE BY MEASURING ADIPONECTIN

#118
20080221057
2008-09-11

SECRETED PROTEIN CCDC80 REGULATES ADIPOCYTE DIFFERENTIATION

#119
20080213886
2008-09-04

Albumin fusion proteins

#120
20080207493
2008-08-28

Compounds for Use in the Treatment of Obesity

#121
20080171702
2008-07-17

NOVEL GENE AND USES THEREFOR

#122
20080167240
2008-07-10

Albumin Fusion Proteins

#123
20080167239
2008-07-10

Albumin fusion proteins comprising insulin polypeptides

#124
20080161243
2008-07-03

Albumin Fusion Proteins

#125
20080153751
2008-06-26

G-CSF-albumin fusion proteins

#126
20080152696
2008-06-26

Use of Leptin for the Prevention of Excess Body Weight and Composition Containing Leptin

#127
20080146503
2008-06-19

Albumin fusion proteins

#128
20080108567
2008-05-08

Leptin-related peptides

#129
20080019940
2008-01-24

Protein conjugates with a water-soluble biocompatible, biodegradable polymer

#130
20070275891
2007-11-29

Nucleic acids encoding OBG3 polypeptides

#131
20070259815
2007-11-08

Albumin fusion proteins

#132
20070244047
2007-10-18

Albumin fusion proteins

#133
20070224193
2007-09-27

Methods of increasing lean tissue mass using OB protein compositions

#134
20070218504
2007-09-20

HUMAN LEPTIN-DERIVED POLYPEPTIDES AND USES THEREOF

#135
20070207148
2007-09-06

GENES ASSOCIATED WITH OBESITY AND METHODS FOR USING THE SAME

#136
20070162987
2007-07-12

Isolated antibodies against biologically active leptin-related peptides

#137
20070141566
2007-06-21

Methods and materials relating to novel polypeptides and polynucleotides

#138
20070054364
2007-03-08

Polypeptide variants

#139
20070054359
2007-03-08

Rational Chemical Modification of Adiponectin Variants

#140
20070021589
2007-01-25

Obesity-related genes

#141
20070020284
2007-01-25

OB fusion protein compositions and methods

#142
20070015909
2007-01-18

Adiponectin variants

#143
20060294612
2006-12-28

GPCR-LIKE RETINOIC ACID-INDUCED GENE 1 PROTEIN AND NUCLEIC ACID

#144
20060281151
2006-12-14

Globular adiponectin variants

#145
20060276396
2006-12-07

Albumin fusion proteins

#146
20060252678
2006-11-09

Homotrimeric extended OBG3 globular head and uses thereof

#147
20060206948
2006-09-14

Compositions for blocking the inhibitory effect of human CRP on human leptin

#148
20060205660
2006-09-14

OB protein-immunoglobulin chimeras

#149
20060194735
2006-08-31

Albumin fusion proteins

#150
20060194233
2006-08-31

Ligand of the protein "beacon"

#151
20060154859
2006-07-13

Leptin antagonists

#152
20060105407
2006-05-18

Protein chip for analyzing interaction between protein and substrate peptide thereof

#153
20060053498
2006-03-09

Full-length human cdnas encoding potentially secreted proteins

#154
20060046959
2006-03-02

Leptin antagonist

#155
20060030530
2006-02-09

Isolated polypeptide comprising a leptin fragment

#156
20060015951
2006-01-19

Proteins involved in the regulation of energy homeostasis

#157
20050288223
2005-12-29

OBG3 Fragments Inhibiting The Conversion Of Active OBG3 Into Less Active OBG3 And Other Compositions For Treatment Of Metabolic Disorders

#158
20050266464
2005-12-01

C1q family member proteins with altered immunogenicity

#159
20050260709
2005-11-24

Lipin1 function

#160
20050250690
2005-11-10

Leptin peptide antagonists

#161
20050214762
2005-09-29

Polypeptide variants

#162
20050203010
2005-09-15

NOVEL PEPTIDES CONFERRING ENVIRONMENTAL STRESS RESISTANCE AND FUSION PROTEINS INCLUDING SAID PEPTIDES

#163
20050186664
2005-08-25

Albumin fusion proteins comprising GLP-1 polypeptides

#164
20050176107
2005-08-11

Methods of increasing lean tissue mass using OB protein compositions

#165
20050163799
2005-07-28

OB fusion protein compositions and methods

#166
20050163779
2005-07-28

Smooth muscle growth inhibitory composition, diagnostic method for arteriosclerosis, and kit therefor

#167
20050158287
2005-07-21

Methods for using the obese gene and its gene product to identify hematopoietic progenitor cells

#168
20050112618
2005-05-26

Secreted protein

#169
20050106679
2005-05-19

Leptin proteins

#170
20050075285
2005-04-07

GSSP4 polynucleotides and polypeptides and uses thereof

#171
20050074767
2005-04-07

Genes associated with obesity and methods for using the same

#172
20050059631
2005-03-17

Nucleic acids encoding OBG3 globular head and uses thereof

#173
20050059108
2005-03-17

Gene associated with regulation of energy balance, obesity and diabetes and uses therefor

#174
20050049193
2005-03-03

Leptin-related peptides

#175
20050042731
2005-02-24

Secreted proteins